Erasca · pitchdeck
Erasca | IPO Presentation Deck | 46 slides
46 pages · 3 arc beats · 2 loops
Erasca | IPO Presentation Deck | 46 slides
Erasca · 2021-07 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
1246810121416182022242628303234363840424446
Deck intelligence map
3 coverage by narrative range · generated from this deck JSON
Narrative range 13 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 2 slides 100% 2/2 slides 100% 2/2 slides · 10 hits — 0/2 slides
100% 2/2 slides 100% 2/2 slides 100% 2/2 slides 100% 2/2 slides Solution 3 slides 100% 3/3 slides 100% 3/3 slides · 13 hits — 0/3 slides
66.7% 2/3 slides · 3 hits 100% 3/3 slides 100% 3/3 slides — 0/3 slides
Traction 8 slides 100% 8/8 slides 100% 8/8 slides · 37 hits — 0/8 slides
37.5% 3/8 slides — 0/8 slides
100% 8/8 slides — 0/8 slides
Slide inventory
46 every slide · same image gating as the playbook
04
The slide combines mission statement, company history, pipeline milestones, and investor logos.inspire_vision
07
The chart uses a waterfall structure to show the cumulative total of patient lives affected across different cancer types and regions.size_opportunity
08
The table uses color coding to distinguish between market types. The 'Red ocean' cells are highlighted in red, while the rest are blue. The bottom rows show geosize_opportunity
09
The slide uses a biological signaling pathway map as a framework to explain the company's therapeutic strategy.present_solution
Open slide detailBeat · Solution
10
The slide uses a Gantt-style chart to represent clinical trial progress across multiple programs.plan_implementation
Open slide detailBeat · Solution
11
The slide uses a biological process diagram to map drug candidates to specific protein targets.present_solution
Open slide detailBeat · Solution
12
The slide uses a checkmark for owned/licensed programs and a 'P' for partnered programs, highlighting Erasca's broad coverage compared to peers.compare_peers
13
The slide uses a biological pathway diagram to illustrate the position of ERK relative to other nodes like MEK and RAF.present_solution
14
The table uses a highlight row for the primary subject (ERAS-007) to draw focus.compare_peers
15
The chart shows a logarithmic scale for IC50 (nM) across different cell lines grouped by mutation status (BRAF, HRAS, KRAS, NRAS, wildtype).compare_peers
17
The slide uses red dashed boxes to highlight the sustained suppression of P-RSK, a marker of MAPK pathway reactivation, specifically showing ERAS-007's superioranalyze_data
18
The slide uses a comparative experimental design to demonstrate the superior efficacy of ERAS-007 in a specific biological pathway.present_solution
19
Data shows efficacy of ERAS-007 in combination with Encorafenib and Cetuximab in BRAF-mutant colorectal cancer models.show_traction
Open slide detailBeat · Traction
20
The slide demonstrates efficacy in two distinct models (HCC827/ER1 and NCI-H820).show_traction
Open slide detailBeat · Traction
21
The slide presents preclinical efficacy data for ERAS-007 in two different KRAS-mutant cancer models.show_traction
Open slide detailBeat · Traction
22
The chart displays individual patient responses (waterfall plot) categorized by dose level.show_traction
Open slide detailBeat · Traction
23
The chart uses color to represent dosage and symbols to represent clinical response (Partial Response, Stable Disease, Progressive Disease).show_traction
Open slide detailBeat · Traction
24
Includes patient history details (genetics, prior treatments, dosage) for two case studies.show_traction
Open slide detailBeat · Traction
25
The slide highlights that QW dosing is better tolerated, specifically noting less rash and manageable side effects compared to QD dosing.compare_peers
Open slide detailBeat · Traction
26
The table highlights the safety profile of the drug candidate in a clinical trial setting.analyze_data
Open slide detailBeat · Traction
27
The slide uses a line chart to show drug concentration over time and a table to summarize key PK/PD metrics (Cmax, Cmin, T>IC90, T<IC50).analyze_data
28
The slide uses a biological pathway diagram to illustrate the mechanism of action for SHP2 inhibitors.present_solution
29
The slide uses a table to contrast the target (SHP2) against a panel of off-target phosphatases.present_solution
31
IC50 values represent potency; lower values indicate higher potency.compare_peers
32
The slide presents technical pharmacological data to support the drug's viability.analyze_data
33
TGI = Tumor Growth Inhibition. Data shows mean tumor volume over time.show_traction
35
CRC KRAS G12C PDX CO-04-0310 model used for efficacy and safety assessment.show_traction
36
The slide uses a hierarchical process flow to illustrate the progression of clinical trial cohorts.plan_implementation
37
The chart shows Day 1 and Day 15 profiles with a reference line for pERK H358 IC50/fu.show_traction
38
The slide uses a scientific mechanism of action diagram to illustrate the inhibition of the GEF binding region.argue_timing
Open slide detailLoop · Golden Circle
39
The table uses directional arrows (green up, yellow horizontal, orange down) to indicate performance relative to reference compounds.analyze_data
Open slide detailLoop · Golden Circle
40
TGI = Tumor Growth Inhibition. CDX = Cell line-derived xenograft. MIA PaCa-2 is a human pancreatic cancer cell line.analyze_data
41
The slide presents preclinical efficacy and safety data for the lead candidate ERAS-3490.present_solution
42
The slide highlights the technical challenge of targeting the active GTP state and introduces specific programs (ERAS-4 and ERAS-2/3) to address this.present_solution
44
The slide uses a heatmap-style table with overlays to indicate specific clinical trial programs (HERKULES-1/2/3/4, FLAGSHP-1) mapped against patient population size_opportunity
45
The slide uses a horizontal timeline format to map specific program milestones to calendar periods.plan_implementation